Биомаркеры стратификации риска у больных фибрилляцией предсердий и хронической болезнью почек


В.В. Фомин, Г.Г. Киякбаев

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» МЗ РФ, Москва
Недавние исследования биомаркеров в популяции больных фибрилляцией предсердий показали, что их применение может улучшить стратификацию риска. Показано, что сердечные биомаркеры, такие как тропонины и натрий-уретические пептиды, в сочетании с имеющимися клиническими моделями стратификации риска позволяют лучше прогнозировать возможность развития осложнений. Аналогичные данные имеют место также в отношении биомаркеров функции почек и коагуляции.

Литература


  1. Ronco C., McCullough P., Anker S. Acute Dialysis Quality Initiative consensus group // Eur. Heart J. – 2010. – Vol. 31. – P. 703–711.
  2. Benjamin E.J., Wolf P.A., D’Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study // Circulation. – 1998. – Vol. 98. – P. 946–952.
  3. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study // Stroke. – 1991. – Vol. 22. – P. 983–988.
  4. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., Singer D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study // J Am Med Assoc. – 2001. – Vol. 285. – P. 2370–2375.
  5. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates // Am J Cardiol. – 1998. – Vol. 82. – P. 2N–9N.
  6. Daoud E.G., Bogun F., Goyal R., Harvey M., Man K.C., Strickberger S.A., Morady F. Effect of atrial fibrillation on atrial refractoriness in humans // Circulation. – 1996. – Vol. 94. – P. 1600–1606.
  7. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation // Circulation. – 1997. – Vol. 96. – P. 1180–1184.
  8. Savelieva I., John Camm A. Atrial fibrillation and heart failure: natural history and pharmacological treatment // Europace. – 2004. – Vol. 5 (Suppl. 1). – P. S5–S19.
  9. Tsang T.S., Gersh B.J., Appleton C.P., Tajik A.J., Barnes M.E., Bailey K.R., Oh J.K., Leibson C., Montgomery S.C., Seward J.B. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women // J Am Coll Cardiol. – 2002. – Vol. 40. – P. 1636–1644.
  10. Haissaguerre M., Jais P., Shah D.C., Takahashi A., Hocini M., Quiniou G., Garrigue S., Le Mouroux A., Le Metayer P., Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins // N Engl J Med. – 1998. – Vol. 339. – P. 659–666.
  11. Group. SRiAFW. Independent predictors of stroke in patients with atrial fibrillation: a systematic review // Neurology. – 2007. – Vol. 69. – P. 546–554.
  12. Hughes M., Lip G.Y. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data // Thromb Haemost. – 2008. – Vol. 99. – P. 295–304.
  13. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., Van Gelder I.C., Al-Attar N., Hindricks G., Prendergast B., Heidbuchel H., Alfieri O., Angelini A., Atar D., Colonna P., De Caterina R., De Sutter J., Goette A., Gorenek B., Heldal M., Hohloser S.H., Kolh P., Le Heuzey J.Y., Ponikowski P., Rutten F.H. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) // Eur Heart J. – 2010. – Vol. 31. – P. 2369–2429.
  14. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation // Chest. – 2010. – Vol. 137. – P. 263–272.
  15. Antman E.M., Tanasijevic M.J., Thompson B., Schactman M., McCabe C.H., Cannon C.P., Fischer G.A., Fung A.Y., Thompson C., Wybenga D., Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes // N Engl J Med. – 1996. – Vol. 335. – P. 1342–1349.
  16. Katus H.A., Remppis A., Neumann F.J., Scheffold T., Diederich K.W., Vinar G., Noe A., Matern G., Kuebler W. Diagnostic efficiency of troponin T measurements in acute myocardial infarction // Circulation. – 1991. – Vol. 83. – P. 902–912.
  17. James S.K., Armstrong P., Barnathan E., Califf R., Lindahl B., Siegbahn A., Simoons M.L., Topol E.J., Venge P., Wallentin L. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy // J Am Coll Cardiol. – 2003. – Vol. 41. – P. 916–924.
  18. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease // N Engl J Med. – 2000. – Vol. 343. – P. 1139–1147.
  19. Horwich T.B., Patel J., MacLellan W.R., Fonarow G.C. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure // Circulation. – 2003. – Vol. 108. – P. 833–838.
  20. Omland T., de Lemos J.A., Sabatine M.S., Christophi C.A., Rice M.M., Jablonski K.A., Tjora S., Domanski M.J., Gersh B.J., Rouleau J.L., Pfeffer M.A., Braunwald E. A sensitive cardiac troponin T assay in stable coronary artery disease // N Engl J Med. – 2009. – Vol. 361. – P. 2538–2547.
  21. Zethelius B., Johnston N., Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study // Circulation. – 2006. – Vol. 113. – P. 1071–1078.
  22. Hijazi Z., Oldgren J., Andersson U., Connolly S.J., Ezekowitz M.D., Hohnloser S.H., Reilly P.A., Vinereanu D., Siegbahn A., Yusuf S., Wallentin L. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy // Circulation. – 2012. – Vol. 125. – P. 1605–1616.
  23. Wallentin L., Hijazi Z., Siegbahn A., Schollin M., Alexander J.H., Atar D., Bernard, Gersh B.J., Hanna M., Harjola V.P., Horowitz J., Husted S., Hylek E.M., Lopes R.D., McMurray J.J.V., Granger C.B. on behalf of the ARISTOTLE Investigators. High sensitivity troponin-T for risk stratification in atrial fibrillation during treatment with apixaban or warfarin // European Heart Journal. – 2012. – Vol. 33.
  24. Daniels L.B., Maisel A.S. Natriuretic peptides // J Am Coll Cardiol. – 2007. – Vol. 50. – P. 2357–2368.
  25. Johnston N., Jernberg T., Lindahl B., Lindback J., Stridsberg M., Larsson A., Venge P., Wallentin L. Biochemical indicators of cardiac and renal function in a healthy elderly population // Clin Biochem. – 2004. – Vol. 37. – P. 210–216.
  26. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C.Jr. Plasma brain natriuretic peptide concentration: impact of age and gender // JAm Coll Cardiol. – 2002. – Vol. 40. – P. 976–982.
  27. Boomsma F., van den Meiracker A.H. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use // Cardiovasc Res. – 2001. – Vol. 51. – P. 442–449.
  28. Ellinor P.T., Low A.F., Patton K.K., Shea M.A., Macrae C.A. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation // J Am Coll Cardiol. – 2005. – Vol. 45. – P. 82–86.
  29. Shelton R.J., Clark A.L., Goode K., Rigby A.S., Cleland J.G. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation // Eur Heart J. – 2006. – Vol. 27. – P. 2353–2361.
  30. Silvet H., Young-Xu Y., Walleigh D., Ravid S. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation // Am J Cardiol. – 2003. – Vol. 92. – P. 1124–1127.
  31. Jourdain P., Bellorini M., Funck F., Fulla Y., Guillard N., Loiret J., Thebault B., Sadeg N., Desnos M. Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study // Eur J Heart Fail. – 2002. – Vol. 4. – P. 263–267.
  32. Wozakowska-Kaplon B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation // Am J Cardiol. – 2004. – Vol. 93. – P. 1555–1558.
  33. Yamada T., Murakami Y., Okada T., Okamoto M., Shimizu T., Toyama J., Yoshida Y., Tsuboi N., Ito T., Muto M., Kondo T., Inden Y., Hirai M., Murohara T. Plasma atrial natriuretic Peptide and brain natriuretic Peptide levels after radiofrequency catheter ablation of atrial fibrillation // Am J Cardiol. – 2006. – Vol. 97. – P. 1741–1744.
  34. Beck-da-Silva L., de Bold A., Fraser M., Williams K., Haddad H. Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm // Can J Cardiol. – 2004. – Vol. 20. – P. 1245–1248.
  35. Freynhofer M.K., Jarai R., Hochtl T., Bruno V., Vogel B., Aydinkoc K., Nurnberg M., Wojta J., Huber K. Predictive value of plasma NT-proBNP and body mass index for recurrence of atrial fibrillation after cardioversion // Int J Cardiol. – 2011. – Vol. 149. – P. 257–259.
  36. Lellouche N., Berthier R., Mekontso-Dessap A., Braconnier F., Monin J.L., Duval A.M., Dubois-Rande J.L., Gueret P., Garot J. Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion // Am J Cardiol. – 2005. – Vol. 95. – P. 1380–1382.
  37. Patton K.K., Ellinor P.T., Heckbert S.R., Christenson R.H., DeFilippi C., Gottdiener J.S., Kronmal R.A. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study // Circulation. – 2009. – Vol. 120. – P. 1768–1774.
  38. Hijazi Z., Wallentin L., Siegbahn A., Andersson U., Christersson C., Ezekowitz J., Gersh B.J., Hanna M., Hohnloser S., Horowitz J., Huber K., Hylek E.H., Lopes E.D., McMurray J.J.V., Granger C.B. NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin // European Heart Journal. – 2012. – Vol. 33.
  39. Shibazaki K., Kimura K., Fujii S., Sakai K., Iguchi Y. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke // Am J Cardiol. – 2012. – Vol. 109. – P. 1303–1307.
  40. Goetze J.P., Friis-Hansen L., Rehfeld J.F., Nilsson B., Svendsen J.H. Atrial secretion of B-type natriuretic peptide // Eur Heart J. – 2006. – Vol. 27. – P. 1648–1650.
  41. Inoue S., Murakami Y., Sano K., Katoh H., Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation // J Card Fail. – 2000. – Vol. 6. – P. 92–96.
  42. Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M., Ogawa H., Okumura K., Mukoyama M., Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure // Circulation. – 1994. – Vol. 90. – P. 195–203.
  43. Asselbergs F.W., van den Berg M.P., Bakker S.J. N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort // Neth. Heart J. – 2008. – Vol. 16(3). – P. 73–78.
  44. Wozakowska-Kapłon B., Opolski G., Herman Z. Natriuretic peptides in patients with atrial fibrillation // Cardiol. J. – 2008. – Vol. 15(6). – P. 525–529.
  45. Sakuma M., Nakamura M., Tanaka F. Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population // Circ. J. – 2010.
  46. Al Suwaidi J., Reddan D.N., Williams K., Pieper K.S., Harrington R.A., Califf R.M., Granger C.B., Ohman E.M., Holmes D.R.Jr. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes // Circulation. – 2002. – Vol. 106. – P. 974–980.
  47. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N Engl J Med. – 2004. – Vol. 351. – P. 1296–305.
  48. Santopinto J.J., Fox K.A., Goldberg R.J., Budaj A., Pinero G., Avezum A., Gulba D., Esteban J., Gore J.M., Johnson J., Gurfinkel E.P. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE) // Heart. – 2003. – Vol. 89. – P. 1003–1008.
  49. Ananthapanyasut W., Napan S., Rudolph E.H., Harindhanavudhi T., Ayash H., Guglielmi K.E., Lerma E.V. Prevalence of atrial fibrillation and its predictors in non-dialysis patients with chronic kidney disease // Clin J Am Soc Nephrol. – 2010. – Vol. 5. – P. 173–181.
  50. Deo R., Katz R., Kestenbaum B., Fried L., Sarnak M.J., Psaty B.M., Siscovick D.S., Shlipak M.G. Impaired kidney function and atrial fibrillation in elderly subjects // J Card Fail. – 2010. – Vol. 16. – P. 55–60.
  51. Genovesi S., Pogliani D., Faini A., Valsecchi M.G., Riva A., Stefani F., Acquistapace I., Stella A., Bonforte G., DeVecchi A., DeCristofaro V., Buccianti G., Vincenti A. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients // Am J Kidney Dis. – 2005. – Vol. 46. – P. 897–902.
  52. Iguchi Y., Kimura K., Kobayashi K., Aoki J., Terasawa Y., Sakai K., Uemura J., Shibazaki K. Relation of atrial fibrillation to glomerular filtration rate // Am J Cardiol. – 2008. – Vol. 102 .– P. 1056–1059.
  53. McManus D.D., Corteville D.C., Shlipak M.G., Whooley M.A., Ix J.H. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study) // Am J Cardiol. – 2009. – Vol. 104. – P. 1551–1555.
  54. Berkowitsch A., Kuniss M., Greiss H., Wojcik M., Zaltsberg S., Lehinant S., Erkapic D., Pajitnev D., Pitschner H.F., Hamm C.W., Neumann T. Impact of impaired renal function and metabolic syndrome on the recurrence of atrial fibrillation after catheter ablation: a long term follow-up // Pacing Clin Electrophysiol. – 2012. – Vol. 35. – P. 532–543.
  55. Chao T.F., Lin Y.J., Chang S.L., Lo L.W., Hu Y.F., Tuan T.C., Suenari K., Li C.H., Chen S.A. Associations between renal function, atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation // Circ J. – 2011. – Vol. 75. – P. 2326–2332.
  56. Schmidt M., Daccarett M., Rittger H., Marschang H., Holzmann S., Jung P., Bojanic D., Ketteler M., Brachmann J., Rieber J. Renal dysfunction and atrial fibrillation recurrence following cardioversion // J Cardiovasc Electrophysiol. – 2011. – Vol. 22. – P. 1092–1098.
  57. Schmidt M., Rieber J., Daccarett M., Marschang H., Sinha A.M., Biggar P., Jung P., Ketteler M., Brachmann J., Rittger H. Relation of recurrence of atrial fibrillation after successful cardioversion to renal function // Am J Cardiol. – 2010. – Vol. 105. – P. 368–372.
  58. Go A.S., Fang M.C., Udaltsova N., Chang Y., Pomernacki N.K., Borowsky L., Singer D.E. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study // Circulation. – 2009. – Vol. 119. – P. 1363–1369.
  59. Hohnloser S.H., Hijazi Z., Thomas L., Alexander J.H., Amerena J., Hanna M., Keltai M., Lanas F., Lopes R.D., Lopez-Sendon J., Granger C.B., Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial // Eur Heart J. – 2012. – Vol. 33. – P. 2821–2830.
  60. Abrahamson M., Olafsson I., Palsdottir A., Ulvsback M., Lundwall A., Jensson O., Grubb A. Structure and expression of the human cystatin C gene // Biochem J. – 1990. – Vol. 268. – P. 287–294.
  61. Laterza O.F., Price C.P., Scott M.G. Cystatin C: an improved estimator of glomerular filtration rate? // Clin Chem. – 2002. – Vol. 48. – P. 699–707.
  62. Newman D.J., Thakkar H., Edwards R.G., Wilkie M., White T., Grubb A.O., Price C.P. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine // Kidney Int. – 1995. – Vol. 47. – P. 312–318.
  63. Dubin R., Cushman M., Folsom A.R., Fried L.F., Palmas W., Peralta C.A., Wassel C., Shlipak M.G. Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis // BMC Nephrol. – 2011. – Vol. 12. – P. 3.
  64. Imai A., Komatsu S., Ohara T., Kamata T., Yoshida J., Miyaji K., Shimizu Y., Takewa M., Hirayama A., Deshpande G.A., Takahashi O., Kodama K. Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography // Atherosclerosis. – 2011.
  65. Knight E.L., Verhave J.C., Spiegelman D., Hillege H.L., de Zeeuw D., Curhan G.C., de Jong P.E. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement // Kidney Int. – 2004. – Vol. 65. – P. 1416–1421.
  66. Wang J., Sim A.S., Wang X.L., Salonikas C., Moriatis M., Naidoo D., Wilcken D.E. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease // Atherosclerosis. – 2008. – Vol. 197. – P. 853–859.
  67. Ix J.H., Shlipak M.G., Chertow G.M., Whooley M.A. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study // Circulation. – 2007. – Vol. 115. – P. 173–179.
  68. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.O., Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome // Circulation. – 2004. – Vol. 110. – P. 2342–2348.
  69. Shlipak M.G., Katz R., Sarnak M.J., Fried L.F., Newman A.B., Stehman-Breen C., Seliger S.L., Kestenbaum B., Psaty B., Tracy R.P., Siscovick D.S. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease // Ann Intern Med. – 2006.– Vol. 145. – P. 237–246.
  70. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., Siscovick D.S., Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons // N Engl J Med. – 2005. – Vol. 352. – P. 2049–2060.
  71. Shlipak M.G., Wassel Fyr C.L., Chertow G.M., Harris T.B., Kritchevsky S.B., Tylavsky F.A., Satterfield S., Cummings S.R., Newman A.B., Fried L.F. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study // J Am Soc Nephrol. – 2006. – Vol. 17. – P. 254–261.
  72. Hijazi Z., Oldgren J., Andersson U., Connolly S.J., Ezekowitz M.D., Hohnloser S.H., Reilly P.A., Siegbahn A., Yusuf S., Wallentin L. Cystatin C is Prognostic for Stroke, Death and Bleeding during anticoagulation of atrial fibrillation - a RELY substudy // Circulation. – 2011.
  73. Marín R., Rodríguez P., Tranche S., MAGAL group. Prevalence of abnormal urinary albumin excretion rate in hypertensive atients with impaired fasting glucose and its association with cardiovascular disease // J. Am. Soc. Nephrol. – 2006. – Vol. 17(12 Suppl 3). – P. S178–S188.
  74. Tebbe U., Bramlage P., Thoenes M. Prevalence of microalbuminuria and its associated cardiovascular risk: German and Swiss results of the recent global i-SEARCH survey // Swiss Med. Wkly. – 2009. – Vol. 139(33–34). – P. 473–480.
  75. Asselbergs F.W., van den Berg M.P., Diercks G.F. C-reactive protein and microalbuminuria are associated with atrial fibrillation // Int. J. Cardiol. – 2005. – Vol. 98(1). – P. 73–77.
  76. Böhm M., Thoenes M., Neuberger HR. Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients // Eur. Heart J. – 2009. – Vol. 30(11). – P. 1364–1371.
  77. Asakura H., Hifumi S., Jokaji H., Saito M., Kumabashiri I., Uotani C., Morishita E., Yamazaki M., Shibata K., Mizuhashi K. Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation // Blood Coagul Fibrinolysis. – 1992. – Vol. 3. – P. 469–473.
  78. Gustafsson C., Blomback M., Britton M., Hamsten A., Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation // Stroke. – 1990. – Vol. 21. – P. 47–51.
  79. Kumagai K., Fukunami M., Ohmori M., Kitabatake A., Kamada T., Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation // J Am Coll Cardiol. – 1990. – Vol. 16. – P. 377–380.
  80. Lip G.Y., Lowe G.D., Rumley A., Dunn F.G. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment // Br Heart J. – 1995. – Vol. 73. – P. 527–533.
  81. Marin F., Roldan V., Climent V.E., Ibanez A., Garcia A., Marco P., Sogorb F., Lip G.Y. Plasma vonWillebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation // Heart. – 2004. – Vol. 90. – P. 1162–1166.
  82. Habara S., Dote K., Kato M., Sasaki S., Goto K., Takemoto H., Hasegawa D., Matsuda O. Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation // Eur Heart J. – 2007. – Vol. 28. – P. 2217–2222.
  83. Ohara K., Inoue H., Nozawa T., Hirai T., Iwasa A., Okumura K., Lee J.D., Shimizu A., Hayano M., Yano K. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation // Int J Cardiol. – 2008. – Vol. 126. – P. 316–321.
  84. Somloi M., Tomcsanyi J., Nagy E., Bodo I., Bezzegh A. D-dimer determination as a screening tool to exclude atrial thrombi in atrial fibrillation // Am J Cardiol. – 2003. – Vol. 92. – P. 85–87.
  85. Sadanaga T., Sadanaga M., Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy // J Am Coll Cardiol. – 2010. – Vol. 55. – P. 2225–2231.
  86. Vene N., Mavri A., Kosmelj K., Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy // Thromb Haemost. – 2003. – Vol. 90. – P. 1163–1172.
  87. Eikelboom J., Hijazi Z., Oldgren J., Andersson U., Connolly S.J., Ezekowitz M.D., Reilly P.A., Yusuf S., Wallentin L., Siegbahn A. D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation – a RELY Substudy // Circulation. – 2010. – Vol. 122. – P. A18321.
  88. Christersson C., Schollin M., Alexander J.H., Bersh B.J., Horowitz J., Hylek E.M., Mohan P., Granger C.B., Wallentin L., Siegbahn A. Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death // European Heart Journal. – 2012. – Vol. 33.
  89. Siegbahn A., Christersson C., Schollin M., Alexander J.H., Horowitz J., Hylek E.M., Lopes R.D., Mohan P., Granger C.B., Wallentin L. Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy // European Heart Journal. – 2012. – Vol. 33.
  90. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции // Клиническая нефрология. – 2014. – № 2. – С. 4–29.


Об авторах / Для корреспонденции


Информация об авторах:
Фомин В.В. – д.м.н., профессор кафедры внутренних, профессиональных болезней и пульмонологии МПФ, проректор по лечебной ГБОУ ВПО
«Первый МГМУ им. И.М. Сеченова» Минздрава России.
E-mail: fomin_vic@mail.ru
Киякбаев Г.Г. – ассистент кафедры внутренних профессиональных
болезней и пульмонологии МПФ ГБОУ ВПО «Первый МГМУ
им. И.М. Сеченова» Минздрава России


Похожие статьи


Бионика Медиа